Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 270-192-0 | CAS number: 68412-48-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://chesar.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Endpoint summary
Administrative data
Key value for chemical safety assessment
- Toxic effect type:
- dose-dependent
Effects on fertility
Description of key information
Combined repeated dose toxicity study with the reproductive/developmental screening study:
The NOAEL for Reproductive effects was considered to be 1000 mg/kg bw/day.
The NOAEL for Pup development and survival was considered to be 1000 mg/kg bw/day.
The NOAEL for Systemic toxicity for the adults was considered to be 1000 mg/kg bw/day.
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 16 November 2018 - 23 January 2019
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- see "any other information on materials and methods incl. tables" for further details.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- yes
- Justification for study design:
- In accordance with OECD test guidelines
- Specific details on test material used for the study:
- Name: AMINOX®
CAS number: 68412-48-6
Batch/lot number: T7C16001
Description: Green to brown flakes
Purity: Considered as 100% (as a UVCB)
Expiry date: 14 March 2019
Storage condition: Controlled room temperature (15-25 °C, below 70 RH%)
Safety precautions: Routine safety precautions for unknown materials (lab coat, gloves, safety glasses and face mask) were applied to assure personnel health and safety. - Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI Wistar rats
- Details on species / strain selection:
Justification of species/strain: The rat is regarded as a suitable species for toxicology and reproduction toxicology studies. Wistar rat was selected due to experience with this strain of rat in toxicity and reproduction toxicity studies and known fertility. Crl:WI rats were used for Dose Range Finding study (study code: 17/174-220PE [4]).- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Species and strain: Crl:WI Wistar rats
Source: Charles River Laboratories, Research Models and Services, Germany GmbH (Sandhofer Weg 7,
D-97633, Sulzfeld, Germany, from SPF colony.
Housing conditions: Standard laboratory conditions
Number of animals: 55 male and 55 female rats in the acclimatisation/pre-treatment period, then 48 male and 48 female rats for dosing (12 animals/sex/group for treatment, 4 groups). The additional 7 spare animals/sex were excluded during the randomisation.
Age of animals: Young adult rats, approximately 11-13 weeks old at start of treatment and 13-15 weeks old at mating.
Body weight range: Males: 393 – 460 g, females: 230 – 323 g; did not exceed ± 20 % of the mean weight for each sex at onset of treatment.
Acclimation period: 22 days
Husbandry
Animal health: Only healthy animals were used for the test, as certified by the staff Veterinarian. Females were nulliparous and non-pregnant.
Room number: 239
Cage type: Type II and III polycarbonate
Bedding and nesting: LIGNOCEL® ¾ S certified wooden chips (batch number: 03018180719, expiry date: 19 July 2021) produced by J. Rettenmaier & Söhne GmbH+Co.KG (Holzmühle 1, D-73494 Rosenberg, Germany) were used in the study.
Arbocel® nest building material (batch number: 05072180528, expiry date: 28 May 2021) produced by J. Rettenmaier & Söhne GmbH+Co.KG (Holzmühle 1, D-73494 Rosenberg, Germany). Details of bedding and nest building material were archived with the raw data.
Light: 12 hours daily, from 6.00 a.m. to 6.00 p.m.
Temperature: 19.2 – 25.3 °C (target range 22 ± 3 °C)
Relative humidity: 23 – 60 % (target range 30-70 %)
Ventilation: 15-20 air exchanges/hour
Housing/Enrichment: Rodents were group-housed, up to 2 animals of the same sex and dose group/cage with the exception of the mating and gestation/delivery period when they were paired or individually housed, respectively. Group housing allowed social interaction and the deep wood sawdust bedding allowed digging and other normal rodent activities (i.e. nesting).
Environmental parameters (temperature and relative humidity) were continuously measured, minimum and maximum values were recorded twice a day during the study.
Food and water supply
Animals received ssniff® SM R/M "Autoclavable complete diet for rats and mice –breeding and maintenance" produced by ssniff Spezialdiäten GmbH, D-59494 Soest Germany (batch number: 840 33675, expiry date: 31 January 2019 and batch
number: 639 38520, expiry date: 30 April 2019), ad libitum, and tap water from the municipal supply, as for human consumption from a 500 mL bottle, ad libitum. The food is considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study. The supplier provided analytical certificates for the batches used, which are archived with the raw data.
Water quality control analysis was performed at least once every three months and microbiological assessment is performed monthly, by Veszprém County Institute of State Public Health and Medical Officer Service (ÁNTSZ, H-8201 Veszprém, József A. u. 36., Hungary). The quality control results are archived with the raw data at Citoxlab Hungary Ltd.
Animal identification
Each adult/parental animal (P Generation) was identified by a unique number within the study, written with indelible ink on the tail and cross-referenced to the Animal Master File at Citoxlab Hungary Ltd.
During the pre-exposure period, animals were identified with temporary numbers only. After this 2-week period, a randomisation was performed based on the body weights and the selected animals received their final animal numbers, as follows:
This number consisted of 4 digits, the first digit being the group number, the second, 0 for the males and 5 for the females, and the last 2, the animal number within the group, as indicated in the Experimental design section. The boxes were arranged in such a way that possible effects due to cage placement were minimized and were identified by cards showing the study code, sex, dose group, cage number and individual animal numbers, date of mating and delivery.
Identification of the new-borns (Offspring, F1 Generation) was performed by ink marking of the digit-tips up to one day after birth,
Randomisation
All adult/parental (P) male and female animals were sorted according to body weight by computer and divided into weight ranges before the first exposure (Day 0). There were an equal number of animals from each weight group randomly assigned to each dose group to ensure that animals of all test groups were as nearly as practicable of a uniform weight. This process was controlled by the software PROVANTIS v.9, to verify the homogeneity/variability between/within the groups. Males and females were randomised separately. - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- The dosing solutions were administered to the test item or vehicle-treated (control) animals daily on a 7 days/week basis, by oral gavage using a tipped gavage needle attached to a syringe. A constant volume of 5 mL/kg bw were administered to all animals. The actual volume to be administered were calculated and adjusted based on each animal’s most recent body weight.
Dosing of both sexes began, after 22 days of acclimatisation and pre-exposure period (14 days), 2 weeks before mating, during the mating, and was continued up to and including the day before the necropsy.
The first day of dosing of each animal was regarded as Day 0.
Males were dosed for 28 days (14 days pre-mating and 14 days mating/post-mating) and then euthanized and subjected to necropsy examination.
Females were dosed for 14 days pre-mating, during the mating period, through gestation and until the day before the necropsy (13-day post-partum dosing). The day of birth (when parturition was complete) was defined as Day 0 post-partum. Females showing no-evidence of copulation were sacrificed as practical, on 25 days after the day of presumed mating.
All F1 offspring were terminated on Day 13 post-partum (F1 offspring selected for blood sampling on PND4 were terminated on that day). In order to allow for overnight fasting of dams with urine collection on PPD14, the offspring were euthanized on PPD/PND13 and the dams on PPD/PND14. - Details on mating procedure:
- Mating began after the animals had attained full sexual maturity, 2 weeks after the initiation of treatment, with one female and one male from the same dose group (1:1 mating) in a single cage. Females remained with the same male until copulation occurred, for up to 4 days. A vaginal smear was prepared daily during the mating period and stained with 1% aqueous methylene blue solution. The smears were examined with a light microscope. The presence of a vaginal plug or sperm in the vaginal smear was considered as evidence of copulation (Day 0 of pregnancy as defined by the relevant guidelines). Sperm positive females were housed individually.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- SOLUTIONS, MIXTURES
Vehicle: 1,2-Propylene glycol (PG) was the Vehicle.
Diluent: Tetrahydrofuran:acetonitrile 1:9 (V/V) was used as Diluent.
Stock Solution: Approx. 100 mg test item was weighted with 0.01 mg precision into 10 mL volumetric flask and filled up with tetrahydrofuran. The solution was mixed well by hand. The concentrations of the test item was approx. 10 mg/mL.
Working Solution: The concentration of the working solution was 1000 µg/mL.
Calculated amount of Stock Solution was pipetted into 10 mL volumetric flask and filled up to volume with acetonitrile. The solution was mixed well by hand.
Calibration Solutions: The Working Solution was diluted to the 100 – 1000 µg/mL range with Diluent.
The calibration solutions were injected in duplicates.
ANALYTICAL SAMPLE PREPARATION
0.5 mL samples were received from the top, middle and bottom of the formulation vessels and the samples were diluted into the dynamic range of the calibration in one or two steps. All samples were injected in duplicates.
Preparation of Control and 20 mg/mL formulations: 0.5 mL aliquots (measured with 0.1 mg precision) was diluted to 20 mL with Diluent.
Preparation of 60 mg/mL formulation: 0.5 mL aliquots (measured with 0.1 mg precision) was diluted to 20 mL with Diluent.
5000 µL from the intermediate dilution was pipetted into 10 mL volumetric flask and filled up with Diluent.
Preparation of 200 mg/mL formulation: 0.5 mL aliquots (measured with 0.1 mg precision) was diluted to 20 mL with tetrahydrofuran. 1000 µL from the intermediate dilution was pipetted into 10 mL volumetric flask and filled up with acetonitrile. - Duration of treatment / exposure:
- Male and female Wistar rats were treated for 2 weeks pre-mating and then during the mating/post-mating periods. This was 28 days in total for males. Females were treated throughout gestation and up to and including postpartum/lactation day (PPD) 13.
- Frequency of treatment:
- Daily
- Details on study schedule:
- Males were dosed for 28 days (14 days pre-mating and 14 days mating/post-mating) and then euthanized and subjected to necropsy examination.
Females were dosed for 14 days pre-mating, during the mating period, through gestation and until the day before the necropsy (13-day post-partum dosing). The day of birth (when parturition was complete) was defined as Day 0 post-partum. Females showing no-evidence of copulation were sacrificed as practical, on 25 days after the day of presumed mating. - Dose / conc.:
- 100 mg/kg bw/day (nominal)
- Dose / conc.:
- 300 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Control
- No. of animals per sex per dose:
- Five animals per sex per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- All adult/parental (P) male and female animals were sorted according to body weight by computer and divided into weight ranges before the first exposure (Day 0). There were an equal number of animals from each weight group randomly assigned to each dose group to ensure that animals of all test groups were as nearly as practicable of a uniform weight. This process was controlled by the software PROVANTIS v.9, to verify the homogeneity/variability between/within the groups. Males and females were randomised separately.
Rationale for dose selection and route of administration
The dose levels were selected by the Sponsor in consultation with the Study Director based on available acute oral toxicity data (LD50 over 2000 mg/kg bw in rats [3]) and results of the Dose Range Finding (DRF) study performed at the Test Facility (Citoxlab study code: 17/174-220PE [4]), where no adverse effects were seen up to
1000 mg/kg bw/day.
The aim of this study was to use a maximum of 1000 mg/kg bw/day or to induce toxic effects, but ideally no death or suffering at the highest dose and a NOAEL at the lowest dose. Based on the results from the preliminary study, doses of 100, 300 and
1000 mg/kg bw/day were selected for the main study.
The oral route was selected as it is one of the possible routes of human exposure. - Positive control:
- Not specified
- Parental animals: Observations and examinations:
- Clinical observations and functional observation battery (FOB)
All animals:
Animals were inspected for signs of morbidity and mortality twice daily, at the beginning and the end of the working day. General clinical observations were performed daily*, after treatment at approximately the same time with minor variations, or in the afternoon as practical during the working day, as no peak period of effects was noted after dosing during the first few days of treatment. The principles and criteria summarized in the Humane Endpoints Guidance Document (OECD) were taken into consideration [6].
More detailed examinations were performed once before the first exposure (to allow for within-subject comparisons), then at least weekly, in the morning or before treatment. These observations were performed outside the home cage in a standard arena, at similar day times as practical. The animals were monitored for changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions, and autonomic activity (e.g. lachrymation, piloerection, pupil size, and unusual respiratory pattern). Changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypies (e.g. excessive grooming, repetitive circling), difficult or prolonged parturition or bizarre behaviour (e.g. self-mutilation, walking backwards) were also recorded. Special attention was directed towards the observation of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
*Note: No general clinical observations were made on those days when detailed clinical observations were made.
All animals were monitored for pertinent behavioural changes, signs of difficult or prolonged parturition and all signs of toxicity including mortality. Any changes were recorded including their onset, degree and duration as applicable.
On gestation day GD13 and/or 14 the sperm positive females were examined for the presence of vaginal bleeding or “placental sign” (intrauterine extravasation of blood as an early sign of pregnancy in rat).
Assessment of potential test item related neurotoxicity was performed during the last exposure week (males on Day 25; females on PPD9-12). Selected animals were subjected to the functional observation battery including quantitative assessment of grip strength and measurement of landing foot splay and fore/hind limb grip strength. In order to avoid hypothermia of pups, dams were removed from the pups for not more than approximately 30-40 minutes during FOB or 90 minutes during SMART measurement.
To measure the landing foot splay, the fore/hind paws of the rat were painted with ink and the rat was dropped from a horizontal position onto the appropriate record sheet covering the examination table. The distance between the two resulting ink spots for the hind limbs was measured.
Fore/hind limb grip strength was measured using a grip strength meter (Model GS3, Bioseb, Chaville, France), an instrument designed to quantify objectively rodent muscular strength, in order to identify and assess quantitatively any potential effect of the test item. The rats were held appropriately such that the fore limbs were allowed to grip the support bar and gently pulled back until they released the bar; the device measured the maximum grip strength. This was performed 3 times for each animal on each test day. The procedure was repeated with the hind limbs and the appropriate grip support. The results were tabulated with individual and mean data.
Sensory reactivity to different type of stimuli (e.g. auditory, visual and proprioceptive), assessment of grip strength and motor activity was conducted and the general physical condition and behaviour of animals were tested. A modified Irwin test was performed [7].
Parameters including body position, locomotor activity, respiration rate, respiration type, piloerection, head searching, compulsive biting or licking, circling, upright walking, retropulsion, jumping, exophthalmos, twitches, clonic convulsions, tonic convulsions, tremor, startle, transfer arousal, spatial locomotion, gait, posture, limb position, finger approach, finger withdrawal, touch escape response, diarrhoea, diuresis, visual placing, grip strength, body tone, corneal reflex, pinna reflex, toe pinch, grasping reflex, positional struggle, skin, mucous membrane colour, salivation, palpebral closure, lachrymation, limb tone, abdominal tone, tail pinch, righting reflex and vocalisation were evaluated using a scoring system, where score “0” was given when the behaviour or reaction of the animal was considered normal, and -1 or -2, or +1 and +2 was given if the response was less than or more than expected in an untreated animal.
Motor activity assessment was conducted using Automatic Monitoring System of rat locomotor activity SMART v. 2.5 (Harvard Apparatus, Germany). Locomotor activity was monitored by placing each animal individually into an open-field for a 1-hour observation time, when DVD recording of movement was made. Recording was made for a duration of 60 minutes, under dim-light and undisturbed conditions. The DVD was analysed with “SMART” software after all recordings were made to produce the appropriate parameters. The data from all groups was evaluated for distance travelled in 5-minute segments. The data from the 5-minute segments were presented graphically with the intention of showing plateau activity in controls, and comparing the treatment groups.
Body weight measurement
All adult animals were weighed with an accuracy of 1 g at least weekly during the pre-exposure period, then on Day 0 for randomisation purposes, afterwards at least weekly and at termination. Parent females were weighed on gestation Days GD0, 3, 7, 10, 14, 17 and 20 and on post-partal Days PPD0 (within 24 hours after parturition), PPD4, 7, 10, 13 and 14 (before termination). The body weight of the female animals measured on gestational Days GD3, 10 and 17 as well as PPD7 and PPD10 were only additional measurements as aid for the calculation of accurate treatment volumes, thus these data were not evaluated statistically.
Food consumption measurement
Animal food consumption was determined by re-weighing the non-consumed diet with a precision of 1 g weekly (on the days of body weight measurements). - Oestrous cyclicity (parental animals):
- Oestrus cycle monitoring
Oestrus cycles were monitored by vaginal smears daily during the pre-exposure period before the treatments starts (for details see 4.4.5.). Vaginal smears were also checked daily from the beginning of the treatment period until evidence of mating.
Additionally, vaginal smears were prepared and examined for each female on the day of necropsy to determine the stage of oestrus cycle and allow correlation with histopathology of the reproductive organs. - Sperm parameters (parental animals):
- Not specified
- Litter observations:
- Observation of the delivery process, offspring and nursing instinct
Females were allowed to litter and rear their offspring. The delivery process was observed as carefully as possible. All observations were recorded. The duration of gestation was recorded and was calculated from Day 0 of pregnancy until the completion of parturition.
Dams were observed for signs of nest building with the bedding material and for covering their new-borns. Evidence of suckling was observed by the presence of milk in the pups' stomach. All observations were recorded.
Each litter was examined as soon as possible after delivery to establish the number and sex of pups, stillbirths, live births, runts (pups that are apparently smaller than normal pups) and to detect the presence of gross abnormalities. Observations were reported individually for each adult animal. In addition to the observations on parent animals, any abnormal behaviour of the offspring was recorded.
Live pups were counted, sexed, weighed individually within 24 hours of parturition (PND0) and on PND4 and PND13, with accuracy of 0.01g. All litters were checked and recorded daily for the number of viable and dead pups. None of the found dead pups were intact (not cannibalized or autolysed) at the time of detection, therefore they could not be subjected to necropsy for macroscopic examination.
The anogenital distance (AGD) of each pup was measured at the time of the first weighing (PND0). Presence of nipples/areolae in male pups were recorded on PND13 (individual records were maintained). - Postmortem examinations (parental animals):
- At termination, the surviving adult rats were euthanized under pentobarbital anaesthesia, followed by exsanguination.
Gross necropsy was performed on all animals, irrespective of the date of death. After exsanguination the external appearance was examined, cranium, thoracic and abdominal cavities were opened and the appearance of the tissues and organs was observed macroscopically. Any abnormality was recorded with details of the location, colour, shape and size, as appropriate. Special attention was paid to the organs of the reproductive system.
The preterminally euthanized and the found dead animals were examined similarly to the terminal animals.
Vaginal smears were prepared and examined for each female on the day of necropsy to determine the stage of oestrus cycle and allow correlation with histopathology of the reproductive organs.
The number of implantation sites and of corpora lutea were recorded in female animals as applicable.
At the time of termination, body weight and the weight of the following organs from all surviving adult animals were determined:
- With a precision of 0.01 g: uterus (including cervix), testes, epididymides, prostate, seminal vesicles with coagulating glands, brain, heart, kidneys, liver, spleen and thymus
- With a precision of 0.001 g: adrenals, ovaries, thyroids with parathyroids
Testes and epididymides were weighed individually. Individual and/or paired absolute organ weight was reported for each animal and adjusted for the body and brain weights. Paired organ weights as applicable were summarised. Relative organ weight (to body and brain weight) were calculated and reported.
The organ weights of the preterminally euthanized animal were measured similarly to the terminal animals. However, no organ weight measurement was performed in the found dead animal.
For the adult animals, a detailed histological examination was performed as follows:
• on the selected list of retained organs in the Control and High dose groups (selected 5 animals/sex/group),
• on the selected list of retained organs in one High dose female (#4511) that was found dead and in in one Control female (#1509) that was preterminally euthanized.
• all organs where macroscopic findings (abnormalities) were seen,
• retained reproductive organs (testes, epididymides, prostate gland, seminal vesicles with coagulation gland for males and uterus, cervix, ovary, oviduct and vagina for females) of all animals of the Control and High dose groups and of all males that failed to sire and all females that failed to deliver healthy pups.
Special attention was paid to the evaluation of the stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure. Detailed histological examination of the ovaries covered the follicular, luteal, and interstitial compartments of the ovary, as well as the epithelial capsule and ovarian stroma. - Postmortem examinations (offspring):
- Dead pups and pups killed on PND4 and/or PND13 were carefully examined externally for gross abnormalities, where possible. The anaesthetic product was diluted for pups’ euthanasia as required.
- Statistics:
- Group means and standard deviations were calculated from numerical data obtained in the study. The statistical evaluation of appropriate data (marked as † in the list below) was performed with the statistical program package of SAS 9.2 (when using Provantis) or with the program package SPSS PC+4.0 (SPSS Hungary Kft, Budapest).
In case of the SPSS PC+4.0 program package, the heterogeneity of variance between groups will be checked by Bartlett's test. Where no significant heterogeneity is detected, a one-way analysis of variance (ANOVA) is carried out. If the obtained result is significant, then Duncan's Multiple Range test is used to assess the significance of inter-group differences. Where significant heterogeneity is found, the normal distribution of data is examined by Kolmogorow-Smirnow test. In the case of non-normal distribution, the non-parametric method of Kruskal-Wallis One-Way analysis of variance is applied. If a positive result is detected, the inter-group comparisons are performed using Mann-Whitney U-test. The Chi-squared test will be used for non-continuous data
In case of the SAS 9.2 software package (within the validated Provantis system) the following decision tree is applied automatically for statistical evaluation of continuous numeric data.
- Reproductive indices:
- Not specified
- Offspring viability indices:
- Not specified
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Piloerection, hunched back, decreased activity were seen in the found dead animal (#4511) before its death. As the animal died because of a gavage accident, these symptoms are considered not to be test item related.
Piloerection was seen in all other High dose females from Day 35, which disappeared in all animals until Day 41. The High dose animals littered between Day 36 and 40, so this clinical sign was observed around the parturition.
All male animals were symptom-free during the study.
Piloerection, hunched back and decreased activity were seen in the pre-terminally euthanized animal (#1509) before its euthanasia. As the animal was euthanized because of a parturition problem, these symptoms are considered not to be test item related.
The following individual observations were not attributed to systemic effects of the test item: Tonic convulsion in one Control female (#1510) on Day 42, in two Mid dose females (#3501, 3505) on several occasions from Day 41, in one High dose female (#4503) on Day 43, slight noisy respiration in one Low dose female (#2509) on Day 1 and in on Mid dose female (#3512) on Days 10-11, alopecia on all limbs of one High dose female (#4512) from Day 40.
Green discoloured urine was seen in one High dose female (#4505) during the last 3 days before terminal necropsy, the observation was of uncertain relationship with treatment. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- No test item-related mortality was seen during the study.
One High dose female (#4511) was found dead on Day 19. The cause of death was confirmed at necropsy as a gavage accident.
One Control female (#1509) was pre-terminally euthanized due to a problematical parturition (on the 24th day of gestation, Day 40 of dosing), because of animal welfare reasons. The animal gave birth to 6 dead pups and was not able to complete the parturition. Before the euthanasia, blood was seen at the urogenital area besides the other clinical symptoms. - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- In males, significantly lower body weight gain was observed during the first week of treatment in the Mid and High dose groups. After this, the bodyweights were relatively compensated and all male dose groups had similar body weight as the controls at the end of the observation period.
In all female dose groups, body weight loss was observed during the first week of treatment, and lower body weight gains compared to the controls during the second week (pre-mating period). After that, during the gestation period, the test item treated females started to gain weight normally, but still slightly below the control means. After the parturition, during the lactation period, the female body weight gain values became normal, however as a consequence of the earlier lower body weight gains, the female animals’ body weights did not catch up to the control values.
Overall, in both sexes, the first week of treatment was the most significant effect: The Mid and High dose males had reduced body weight gain and the Low, Mid and High dose females had body weight loss. In both sexes, after 1 or 2 weeks of treatment, the body weight gain in all dose groups were near parallel to controls. - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- In males, there were no test item related differences in the mean daily food consumption in any test item treated group when compared to the controls. The measured values were within the normal range for this strain and age.
The food consumption of the females showed similar pattern as the body weight changes; there were statistically significantly lower food consumptions in all dose groups during the pre-mating period, slightly lower food consumption during the gestation period without attaining statistical significance, and generally normal food consumption during the lactation period. - Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No test item-related changes were observed in the haematology parameters. Statistically significant differences were considered to be incidental, there was no relationship with dose and/or all recorded values were within the historical control ranges. These differences were considered to not reflect an effect of the test item.
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No other clear item related clinical chemistry findings were seen. All significant differences were considered to be incidental, there was no relationship with dose and/or all recorded values were near or within the historical control ranges. These differences were considered to not reflect an effect of the test item.
Thyroid hormone levels (adult males): Significantly lower (p<0.05) T4 value was recorded in the High dose group, which was most probably incidental, not related to the test item. As all individual values in the High dose group were well within the historical control range, therefore this difference is not considered toxicologically relevant.
It is considered that there was no evidence that test item had a direct effect on thyroid hormone levels. - Urinalysis findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No clear other test item-related changes were observed in the urinalysis parameters. The significant differences were considered to be incidental, not reflecting an effect of the test item.
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no changes in animal behaviour, general physical condition or in the reactions to different type of stimuli in the control or test groups.
There was no effect of treatment noted during the assessment of grip strength, foot splay or locomotor activity. A statistically significantly lower hind limb foot splay mean in the Mid dose group is considered to be incidental, not test item-related. The High dose group had very similar value to the Control group.
All dose groups of males and females had a normal locomotor activity; in all cases, the initial activity was high, with reduced activity in each 5-minute period to an approximate plateau by about 20-30 minutes. There was no statistical significance between the test item treated animals and the Control when evaluating the overall distance travelled (0-60 min, cm). The test item did not increase or decrease the normal locomotor activity. - Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, non-treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Test item-related findings were seen in the liver of the High dose animals: Minimal centrilobular hypertrophy in 5/5 High dose males and in 1/5 High dose females, minimal to mild hepatocellular vacuolation in 3/5 High dose males. These liver changes at the High dose were considered to be minor treatment related, non-adverse findings.
Besides these observations, based on the low incidence and/or severity and/or distribution cross control and dosed animals, all other observations were considered to be incidental or a common background.
Moderate multifocal degeneration/necrosis of the cardiac muscle cells, severe bilateral chronic progressive nephropathy, mild hepatocellular vacuolation, mild cholangiofibrosis and mild focal/multifocal hepatocellular necrosis in all lobes of the liver and moderate decreased cellularity in the cortex of thymus were recorded in the found dead animal.
Mild focal/multifocal hepatocellular necrosis in all lobes of the liver, minimal focal necrosis in the glandular mucosa of the stomach and mild decreased cellularity in the cortex of the thymus were recorded in the preterminally euthanized animal. These changes were ascribed to the problematical parturition, unrelated to treatment.
Gravidity was confirmed in the uterine. - Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- no effects observed
- Description (incidence and severity):
- Pre-exposure period: Each female selected for the study showed acceptable cycles before starting the treatment period.
Exposure period (pre-mating and mating periods): No indication of test item related effect was seen in the oestrus cycle data, collected during the pre-mating and mating periods). - Reproductive function: sperm measures:
- not examined
- Reproductive performance:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no differences between the control and test item treated groups with regard to reproductive ability, mating or gestation indices, and no effects considered adverse or toxicologically significant in correlation with the administration of the test item. The mating indices were 100% in all groups. The male and female fertility indices were 92% in the Control, 50% in the Low dose group, 67% in the Mid dose group and 92% in the High dose group. Although the number of non-pregnant females in the Low and Mid dose groups were higher than expected, the High dose group had exactly the same incidence as the Control group, therefore it can be concluded that the test item did not have an effect on the reproductive parameters.
Test item administration was considered to have no impact on the duration of the mating period. Successful coitus (sperm positive vaginal smears and/or vaginal plugs) occurred within 3 days of pairing (cohabitation) for all females.
The mean duration of mating was 2.0, 2.3, 2.7 and 2.8 days in the Control, Low,
Mid and High dose groups, respectively.
There was no effect of treatment noted during the gestation period in any of dose groups. The higher pre-natal mortality in the High dose group was caused by one animal (#4502), which lost all of its pups during gestation. Excluding this animal’s data, the mean of the pre-natal mortality in the High dose group would be below the Control. This individual animal’s loss of pups is within the expected range and is not attributed to treatment.
The statistically significantly lower number of implantation sites in the Low dose group was caused by the low number of pregnant animals (non-pregnants are zero values in the mean), and not by lower number of implantation sites in the pregnant animals. The group mean without the non-pregnant animals can be seen in brackets.
The mean duration of pregnancy was comparable in the Control and test item treated groups. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reproductive performance
- Clinical signs:
- not specified
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- The number of viable pups on PND0, 4 and 13 as well as pup survival indices on PND0, 4 and 13 were comparable to control values in each dose group. Overall, there were no treatment-related effects on pup mortality and on the viability of pups on PND0, 4 and 13.
There were no significant differences or effects that could be ascribed to treatment on the pre-natal, post-natal or total mortality values (litter mean and %) in any of the dose groups.
The higher pre-natal and total mortality means in the High dose group was caused by one animal (#4502), which lost all of his pups during gestation. Without this animal, all of these parameters in the High dose group would be below the Control.
The statistically significantly lower number of implantation sites in the Low dose group was caused by the low number of pregnant animals (non-pregnants are zero values in the mean), and not by lower number of implantation sites in the pregnant animals. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no test item related differences in the offspring body weights or weight gains in any test item treated group when compared to the controls. The measured values were within the range commonly recorded for this strain and age.
When evaluated per litter basis, the mean litter body weights and/or body weight gain on PND0, 4 and 13 showed no toxicologically significant differences compared to controls in the F1 generation. - Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- Compared to the control, there were no statistically significant thyroid hormone concentration levels recorded in any of the PND13 pup dose groups.
The thyroid gland weights of the PND13 pups were also statistically not different from the Control group. In summary, there were no effects on the thyroid hormone levels or on the thyroid gland weights in the PND13 pups that were ascribed to the test item.
The measurement of the thyroid hormone levels in the PND4 pups and adult females was not performed as it was not deemed necessary by the Study Director. - Urinalysis findings:
- not examined
- Sexual maturation:
- not examined
- Anogenital distance (AGD):
- effects observed, non-treatment-related
- Description (incidence and severity):
- There were no statistically significant differences in the anogenital distance between the test item treated groups (males/females) and the control on PND0, that were ascribed to the test item. The statistically significantly lower anogenital distance litter mean in the female pups of the Mid dose group is considered incidental, not test-item related.
Two control pups (#1505/9 and 1511/11) we born with short anogenital distance and therefore they were treated as females during the study, however at necropsy the sex of them was determined as male. Because of this, the number of nipples/areolae was not counted in them on PND13.
In summary, there were no effects on the anogenital distance on PND0 - Nipple retention in male pups:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no nipples/areolae presence seen in any of the male pups on PND13.
The presence of nipples/areolae on PND13 that were ascribed to the test item. - Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- None of the pups that were found dead remained intact at the time of detection, thus they could not be subjected to necropsy for macroscopic examination. There were no indications of any treatment related effect.
No test item related macroscopic changes were seen in F1 offspring generation euthanized and examined externally at scheduled termination on PND13.
One control pup had absence of tail. - Histopathological findings:
- not examined
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- mortality
- other: Developmental toxicity
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- In summary, daily administration of AMINOX® by oral gavage to Wistar rats at dose levels of 100, 300 or 1000 mg/kg bw/day, under the conditions of this study, did not result in test item related mortality.
Transient piloerection was seen in the High dose females around the parturition. No changes at neurological assessment were seen at the end of the treatment period.
During the first 1-2 weeks of treatment, the Mid and High dose males had reduced body weight gain and the Low, Mid and High dose females had body weight loss. After that, the body weight gain in all male and female dose groups were near parallel to controls.
At clinical pathology, there were no test item-related findings.
At necropsy, no test item related macroscopic changes were seen. Slightly higher liver weights were recorded in the male High dose group. At histopathology, hepatocellular hypertrophy and vacuolation were seen in the male High dose group. These findings were considered, adaptive, non-adverse changes.
No test item related changes were noted in the reproductive parameters during mating and gestation, delivery and post-partum/lactation period until PPD14. There were no adverse effects on the F1 offspring viability, clinical signs or at observations following euthanasia.
No developmental or endocrine changes were seen in the pups at any of the dose levels (anogenital distance, thyroid gland weights, thyroid hormone level, etc.).
The NOAEL for Reproductive effects was considered to be 1000 mg/kg bw/day.
The NOAEL for Pup development and survival was considered to be 1000 mg/kg bw/day.
The NOAEL for Systemic toxicity for the adults was considered to be 1000 mg/kg bw/day. - Executive summary:
The purpose of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in the Rats was to obtain information on the toxicity of the test item AMINOX® following repeated daily administration by oral gavage to Wistar rats. The study included a reproductive/ developmental toxicity-screening test, intended to provide initial information on possible effects on male and female reproductive performance such as gonadal function, mating behaviour, conception, pregnancy, parturition and development of the F1 offspring from conception to Day 13 post-partum.
Male and female Wistar rats were treated for 2 weeks pre-mating and then during the mating/post-mating periods. This was 28 days in total for males. Females were treated throughout gestation and up to and including postpartum/lactation day (PPD) 13. The Experimental Design was as follows:
Group Number
Group designation
Dose level
(mg/kg bw/day)Concentration
(mg/mL)
Dose volume
(mL/kg bw)
Animal numbers
Male
Female
1
Control
0
0
5
1001-1012
1501-1512
2
Low Dose
100
20
2001-2012
2501-2512
3
Mid Dose
300
60
3001-3012
3501-3512
4
High Dose
1000
200
4001-4012
4501-4512
Parameters measured during the study included signs of morbidity and mortality twice daily, daily and/or weekly detailed observation of clinical signs, neurological assessment, weekly body weight and food consumption, and clinical pathology evaluation, including haematology, coagulation, clinical chemistry and urinalysis. Neurological assessment including functional observation battery (FOB) and measurements of the landing foot splay, grip strength and motor activity were performed during the last week of the treatment. In addition, the reproductive performance, pregnancy, parturition and postpartum/lactation period were monitored in the adult animals, and viability, clinical signs and development were evaluated in their F1 offspring until PND13. At termination, necropsy with macroscopic examination was performed. Weights of selected organs were recorded and representative tissues/organs were sampled and preserved in appropriate fixatives from the adult animals. The thyroxine (T4) levels in the Day 13 pups and adult males were also assessed.
For the adult animals, a detailed histological examination was performed on the selected list of retained organs in the Control and High dose groups.
RESULTS
In summary, daily administration of AMINOX® by oral gavage to Wistar rats at dose levels of 100, 300 or 1000 mg/kg bw/day, under the conditions of this study, did not result in test item related mortality.
Transient piloerection was seen in the High dose females around the parturition. No changes at neurological assessment were seen at the end of the treatment period.
During the first 1-2 weeks of treatment, the Mid and High dose males had reduced body weight gain and the Low, Mid and High dose females had body weight loss. After that, the body weight gain in all male and female dose groups were near parallel to controls.
At clinical pathology, there were no test item-related findings.
At necropsy, no test item related macroscopic changes were seen. Slightly higher liver weights were recorded in the male High dose group. At histopathology, hepatocellular hypertrophy and vacuolation were seen in the male High dose group. These findings were considered, adaptive, non-adverse changes.
No test item related changes were noted in the reproductive parameters during mating and gestation, delivery and post-partum/lactation period until PPD14. There were no adverse effects on the F1 offspring viability, clinical signs or at observations following euthanasia.
No developmental or endocrine changes were seen in the pups at any of the dose levels (anogenital distance, thyroid gland weights, thyroid hormone level, etc.).
The NOAEL for Reproductive effects was considered to be 1000 mg/kg bw/day.
The NOAEL for Pup development and survival was considered to be 1000 mg/kg bw/day.
The NOAEL for Systemic toxicity for the adults was considered to be 1000 mg/kg bw/day.
Reference
The statistically significantly lower number of implantation sites in the Low dose group was caused by the low number of pregnant animals (non-pregnants are zero values in the mean), and not by lower number of implantation sites in the pregnant animals. The group mean without the non-pregnant animals can be seen in brackets.
The mean duration of pregnancy was comparable in the Control and test item treated groups.
Summary of the pre-implantation and gestation periods
Parameters |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Mean number of implantations |
14.83 |
6.67** (13.33) |
10.42 |
12.27 |
Gestation length, mean (days) |
22.64 |
22.67 |
22.75 |
22.78 |
Pre-natal mortality, mean |
2.18 |
0.83 |
1.38 |
2.38 |
Pre-natal mortality (%), mean |
14.19 |
5.48 |
9.03 |
25.35 |
Number of pups born, mean |
14.45 |
12.67 |
14.38 |
11.80 |
Number of live born pups, mean |
13.82 |
12.50 |
14.25 |
11.60 |
Note: *= p<0.05; Duncan’s multiple range test, **= p<0.01; Duncan’s multiple range test. |
Summary of reproductive parameters (females)
Parameters |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Number of days Mating |
2.00 |
2.25 |
2.67 |
2.75 |
Number of treated animals |
12 |
12 |
12 |
12 |
Number of females used for mating |
12 |
12 |
12 |
12 |
Number of sperm positive females |
12 |
12 |
12 |
11 |
Number of females with no implantation sites |
1 |
6 |
4 |
1 |
Number of pregnant females |
11 |
6 |
8 |
9 |
Number of pre-terminal death during gestation |
1 |
0 |
0 |
0 |
Number of pregnant females with live born(s) |
10 |
6 |
8 |
9 |
Number of pre-terminal death during lactation |
0 |
0 |
0 |
0 |
Female mating index (%) |
100 |
100 |
100 |
92 |
Female fertility index (%) |
92 |
50 |
67 |
91 |
Female gestation index (%) |
91 |
100 |
100 |
90 |
Summary of reproductive parameters (males)
Parameters |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Number of treated animals |
12 |
12 |
12 |
12 |
Number of males used for mating |
12 |
12 |
12 |
12 |
Number of pre-terminal death / euthanasia before successful mating |
0 |
0 |
0 |
0 |
Number of successful mating |
12 |
12 |
12 |
12 |
Number of infertile animals |
1 |
6 |
4 |
1 |
Male mating index (%) |
100 |
100 |
100 |
100 |
Male fertility index (%) |
92 |
50 |
67 |
92 |
Parental malethyroid hormone concentration levels
(adult males) |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
T4 concentration (ng/mL) |
45.08 |
43.95 |
44.86 |
37.18+ |
Differences from control |
-3% |
-1% |
-18% |
|
Historical control data |
26.5 – 56.2 |
|||
Notes:+= p<0.05,++= p<0.01; Dunn two sided test |
Significant differences in urinalysis parameters in females
Urinalysis (females) |
Groups/Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Bilirubin |
0.0 |
0.2 |
0.4 |
1.8++ |
Green colour |
0/5 |
1/5 |
3/5 |
3/5 |
Protein (semiquantitative) |
1.6 |
1.2 |
0.6 |
0.0++ |
Notes:+= p<0.05,++= p<0.01; Dunn two sided test |
Significant differences in urinalysis parameters in males
Urinalysis (males) |
Groups/Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Leucocyte (semiquantitative) |
0.6 |
2.0++ |
0.6 |
1.0 |
Notes:+= p<0.05,++= p<0.01; Dunn two sided test |
Significant differences in clinical chemistry parameters in males
Clinical chemistry (males) |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Chloride concentration (mmol/L) |
109.92 |
109.74 |
110.56 |
113.38** |
Differences from control |
-0.2 |
0.6 |
3.1 |
|
Historical control data |
97.2-107.9 |
|||
Alkaline Phosphatase activity (U/L) |
102.6 |
120.8 |
123.8 |
144.2+ |
Differences from control |
17.7% |
20.7% |
40.5% |
|
Historical control data |
65-161 |
|||
Bile acids (mmol/L) |
6.300 |
6.650 |
8.960 |
10.178* |
Differences from control |
5.6% |
42.2% |
61.6% |
|
Historical control data |
6.07-22.69 |
|||
Note: *= p<0.05, **= p<0.01; Dunnett two sided test += p<0.05,++= p<0.01; Dunn two sided test |
Significant differences in haematology parameters in females
Haematology (females) |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Reticulocyte count (%) |
1.76 |
3.18** |
2.48 |
2.68* |
Differences from control |
81% |
41% |
52% |
|
Historical control data |
1.7-4.2 |
|||
Neutrophil (%) |
67.54 |
57.64 |
70.24 |
53.76* |
Differences from control |
-15% |
4% |
-20% |
|
Historical control data |
23.2-75.9 |
|||
Prothrombin Time (sec) |
9.14 |
9.16 |
8.70* |
9.08 |
Differences from control |
0% |
-5% |
-1% |
|
Historical control data |
7.4-9.9 |
|||
Note: *= p<0.05, **= p<0.01; Dunnett two sided test. |
Significant differences in haematology parameters in males
Haematology (males) |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Lymphocyte (%) |
66.68 |
63.68 |
59.04* |
66.30 |
Differences from control |
-5% |
-12% |
-1% |
|
Historical control data |
42.6-79.5 |
|||
Prothrombin Time (sec) |
10.30 |
9.84* |
10.20 |
10.42 |
Differences from control |
-5% |
-1% |
1% |
|
Historical control data |
9.2-10.6 |
|||
Note: *= p<0.05, **= p<0.01; Dunnett two sided test. |
Landing splay test
Foot splay(males) |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Hind limb (mm) |
94.2 |
106.6 |
70.7 * |
95.9 |
Differences from control |
13% |
-25% |
2% |
|
Historical control data |
34 – 136 |
|||
Note: *= p<0.05, **= p<0.01; Dunnett two sided test. |
All test item formulations were shown to be homogeneous. The measured active ingredient concentrations of AMINOX®evaluated for each test item-dose group varied between 98 % and 105 % of the nominal concentrations. The relative standard deviation (RSD) was below 10% in each case. No test item was detected in the control samples. These results were within the acceptable ranges (85% - 115%) and were considered suitable for the study purposes
Summary of analytical results
Nominal |
Measured concentration |
Percentage of the nominal concentration |
Analytical sampling #1(Sampling: 05 December 2018) |
||
Control |
not detectable |
- |
20 |
20.16 ± 0.06 |
100.8 |
60 |
60.07 ± 1.28 |
100.1 |
200 |
195.31 ± 10.05 |
97.7 |
Analytical sampling #2(Sampling: 25 December 2018) |
||
Control |
not detectable |
- |
20 |
20.36 ± 0.16 |
101.8 |
60 |
61.77 ± 0.61 |
103.0 |
200 |
197.69 ± 20.38 |
98.8 |
Analytical sampling #3(Sampling: 16 January 2019) |
||
Control |
not detectable |
- |
20 |
21.07 ± 0.29 |
105.4 |
60 |
62.13 ± 2.33 |
103.6 |
200 |
208.01 ± 7.04 |
104.0 |
Summary of the pre-natal and post-natal periods with survival indices
Parameters |
Group /Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Mean number of implantations |
14.83 |
6.67** |
10.42 |
12.27 |
Number of pups born, mean |
14.45 |
12.67 |
14.38 |
11.80 |
Number of live born pups, mean |
13.82 |
12.50 |
14.25 |
11.60 |
Pre-natal mortality, mean |
2.18 |
0.83 |
1.38 |
2.38 |
Pre-natal mortality (%), mean |
14.19 |
5.48 |
9.03 |
25.35 |
Post-natal mortality on PND0-4, mean |
0.40 |
0.17 |
0.88 |
0.44 |
Post-natal mortality on PND0-4 (%), mean |
2.64 |
0.98 |
6.15 |
3.35 |
Total mortality on PND4, mean |
2.73 |
1.00 |
2.25 |
2.63 |
Total mortality on PND4 (%), mean |
17.60 |
6.40 |
14.52 |
27.04 |
Post-natal mortality on PND0-13, mean |
0.50 |
0.17 |
0.88 |
0.44 |
Post-natal mortality on PND0-13 (%), mean |
3.16 |
0.98 |
6.15 |
3.35 |
Total mortality on PND13, mean |
2.82 |
1.00 |
2.25 |
2.63 |
Total mortality on PND13 (%), mean |
18.05 |
6.40 |
14.52 |
27.04 |
Survival index on PND0(%) |
90.45 |
98.61 |
99.22 |
98.33 |
Sex ratio (% of females) on PND0 |
47.45 |
53.79 |
53.41 |
45.09 |
Survival index on PND4(%) |
97.36 |
99.02 |
93.85 |
96.65 |
Sex ratio (% of females) on PND4 |
46.69 |
54.22 |
52.70 |
46.24 |
Survival index on PND13(%) (from PND4 after culling) |
99.41 |
100.00 |
100.00 |
100.00 |
Sex ratio (% of females) (PND13) |
46.38 |
53.23 |
52.28 |
45.59 |
*= p<0.05; Mann-Whitney U-test, **= p<0.01; Mann-Whitney U-test. |
Details of the offspring mortality andviability
Parameters |
Groups/Concentration (mg/kg bw/day) |
|||
Control (0) |
Low (100) |
Mid (300) |
High (1000) |
|
Number of evaluated litters |
10 |
6 |
8 |
9 |
Number of pups born |
159 |
76 |
115 |
118 |
Number of liveborns |
152 |
75 |
114 |
116 |
Evaluation of PND0 |
||||
Number of found dead / stillborn pups on PND0 |
7 |
1 |
1 |
2 |
Number of cannibalised pups (PND0) |
1 |
1 |
1 |
1 |
Number of autolysed pups (PND0) |
6 |
0 |
0 |
1 |
Number of found dead, intact pups, FT - (PND0) |
0 |
0 |
0 |
0 |
Number of found dead, intact pups, FT + (PND0) |
0 |
0 |
0 |
0 |
Number of viable pups (PND0) |
152 |
75 |
114 |
116 |
Evaluation of PND1-4+ |
||||
Number of dead pups on PND1-4 |
4 |
1 |
7 |
4 |
Number of cannibalised pups (PND1-4) |
4 |
1 |
6 |
4 |
Number of autolysed pups (PND1-4) |
0 |
0 |
1 |
0 |
Number of found dead, intact pups (PND1-4) |
0 |
0 |
0 |
0 |
Number of viable pups (PND4) |
148 |
74 |
107 |
112 |
Number of viable pups after culling (PND4) |
128 |
62 |
91 |
94 |
Evaluation of PND5-13++ |
||||
Number of dead pups on PND5-13 |
1 |
0 |
0 |
0 |
Number of cannibalised pups (PND5-13) |
1 |
0 |
0 |
0 |
Number of autolysed pups (PND5-13) |
0 |
0 |
0 |
0 |
Number of found dead, intact pups (PND5-13) |
0 |
0 |
0 |
0 |
Number of viable pups (PND13) |
127 |
62 |
91 |
94 |
Notes: * = p<0.05, ** = p<0.01; Chi-squared test; +Counted from end of working day PND0. ++Counted from end of working day PND4. Abbreviations: FT - : Floating test negative, FT + : Floating test positive |
Nominal |
Sampling |
cFormula(mg/mL) |
cAverage(mg/mL) |
RecAverage(%) |
RSD (%) |
(mg/mL) |
position |
||||
0 |
Mid |
<LOQ* |
N/A |
N/A |
N/A |
20 |
Top |
20.13 |
20.16 |
100.8 |
0.27 |
Middle |
20.12 |
||||
Bottom |
20.22 |
||||
60 |
Top |
59.00 |
60.07 |
100.1 |
1.89 |
Middle |
61.26 |
||||
Bottom |
59.95 |
||||
200 |
Top |
185.25 |
195.31 |
97.7 |
4.55 |
Middle |
198.59 |
||||
Bottom |
202.07 |
*The LOQ was 100 µg/mL for the analytical samples, which equals to 4 mg/mL formula concentration (counting with 40x dilution during the sample preparation).
All formulations were homogenous.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- K1
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The purpose of this Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test in the Rats was to obtain information on the toxicity of the test item AMINOX® following repeated daily administration by oral gavage to Wistar rats. The study included a reproductive/ developmental toxicity-screening test, intended to provide initial information on possible effects on male and female reproductive performance such as gonadal function, mating behaviour, conception, pregnancy, parturition and development of the F1 offspring from conception to Day 13 post-partum.
Male and female Wistar rats were treated for 2 weeks pre-mating and then during the mating/post-mating periods. This was 28 days in total for males. Females were treated throughout gestation and up to and including postpartum/lactation day (PPD) 13. The Experimental Design was as follows:
Group Number |
Group designation |
Dose level |
Concentration (mg/mL) |
Dose volume (mL/kg bw) |
Animal numbers |
|
Male |
Female |
|||||
1 |
Control |
0 |
0 |
5 |
1001-1012 |
1501-1512 |
2 |
Low Dose |
100 |
20 |
2001-2012 |
2501-2512 |
|
3 |
Mid Dose |
300 |
60 |
3001-3012 |
3501-3512 |
|
4 |
High Dose |
1000 |
200 |
4001-4012 |
4501-4512 |
Parameters measured during the study included signs of morbidity and mortality twice daily, daily and/or weekly detailed observation of clinical signs, neurological assessment, weekly body weight and food consumption, and clinical pathology evaluation, including haematology, coagulation, clinical chemistry and urinalysis. Neurological assessment including functional observation battery (FOB) and measurements of the landing foot splay, grip strength and motor activity were performed during the last week of the treatment. In addition, the reproductive performance, pregnancy, parturition and postpartum/lactation period were monitored in the adult animals, and viability, clinical signs and development were evaluated in their F1 offspring until PND13. At termination, necropsy with macroscopic examination was performed. Weights of selected organs were recorded and representative tissues/organs were sampled and preserved in appropriate fixatives from the adult animals. The thyroxine (T4) levels in the Day 13 pups and adult males were also assessed.
For the adult animals, a detailed histological examination was performed on the selected list of retained organs in the Control and High dose groups.
RESULTS
In summary, daily administration of AMINOX® by oral gavage to Wistar rats at dose levels of 100, 300 or 1000 mg/kg bw/day, under the conditions of this study, did not result in test item related mortality.
Transient piloerection was seen in the High dose females around the parturition. No changes at neurological assessment were seen at the end of the treatment period.
During the first 1-2 weeks of treatment, the Mid and High dose males had reduced body weight gain and the Low, Mid and High dose females had body weight loss. After that, the body weight gain in all male and female dose groups were near parallel to controls.
At clinical pathology, there were no test item-related findings.
At necropsy, no test item related macroscopic changes were seen. Slightly higher liver weights were recorded in the male High dose group. At histopathology, hepatocellular hypertrophy and vacuolation were seen in the male High dose group. These findings were considered, adaptive, non-adverse changes.
No test item related changes were noted in the reproductive parameters during mating and gestation, delivery and post-partum/lactation period until PPD14. There were no adverse effects on the F1 offspring viability, clinical signs or at observations following euthanasia.
No developmental or endocrine changes were seen in the pups at any of the dose levels (anogenital distance, thyroid gland weights, thyroid hormone level, etc.).
The NOAEL for Reproductive effects was considered to be 1000 mg/kg bw/day.
The NOAEL for Pup development and survival was considered to be 1000 mg/kg bw/day.
The NOAEL for Systemic toxicity for the adults was considered to be 1000 mg/kg bw/day.
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Under the conditions of a combined repeated dose / reproductive and developmental screening study there were no significant treatment related effects that were associated with the test substance, therefore according to crtieria specified under regulation 1272/2008 the substance is not classified.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)